Alberto J Espay

Dec 15, 2023 | medscape.com | Kathrin LaFaver |Alberto J Espay

This transcript has been edited for clarity. Kathrin LaFaver, MD: Hello and welcome on behalf of Medscape. I'm Dr Kathrin LaFaver, a neurologist in Saratoga Springs, New York. I have the great pleasure to be talking with my friend, Dr Alberto Espay, today. Alberto is an endowed professor of neurology and the division chief and endowed chair of the Gardner Family Center for Parkinson's Disease and Movement Disorders in Cincinnati.

Jun 12, 2023 | jamanetwork.com | Alberto J Espay |Movement Disorders |Michael Okun

Abandoning the Proteinopathy Paradigm in Parkinson Disease—Not So Fast—Reply In Reply Decades of research have sought not to question but to prove that proteins can turn into toxins, with most efforts focusing on only one side of the protein aggregation story—the pathology. It is worth remembering that pathology today was a normal protein yesterday.

Jun 12, 2023 | jamanetwork.com | Jeff Bronstein |William A. Zeiger |Chao Peng |Alberto J Espay

Abandoning the Proteinopathy Paradigm in Parkinson Disease—Not So Fast To the Editor Espay and Okun1 recently proposed abandoning the proteinopathy paradigm in Parkinson disease (PD) in favor of a “proteinopenia” hypothesis. Loss of function as a possible mechanism for PD and other neurodegenerative diseases is not a new idea, and we agree that multiple potential mechanisms underlying neurodegeneration should be investigated.

May 24, 2023 | neurologylive.com | Alberto J Espay

WATCH TIME: 3 minutesParkinson disease (PD), a progressive neurodegenerative disorder characterized by tremors, has been typically treated with combination of treatments, most notably carbidopa levodopa (CD/LD), followed by other agents such as dopamine agonists and monoamine oxidase B (MAO) inhibitors.

May 24, 2023 | neurologylive.com | Alberto J Espay

WATCH TIME: 3 minutesParkinson disease (PD), a progressive neurodegenerative disorder characterized by tremors, has been typically treated with combination of treatments, most notably carbidopa levodopa (CD/LD), followed by other agents such as dopamine agonists and monoamine oxidase B (MAO) inhibitors.